Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652918 | 0.90 | HTT (0.57) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| SCHEMBL17652919 | 0.90 | HTT (0.57) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| SCHEMBL17652763 | 0.84 | HTT (0.50) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| SCHEMBL17652764 | 0.84 | HTT (0.50) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| Phosphoric Acid SCHEMBL27916059 | 0.82 | HTT (0.58) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| SCHEMBL23051604 | 0.82 | HTT (0.48) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| Phosphoric Acid SCHEMBL28200300 | 0.80 | HTT (0.55) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL27770206 | 0.79 | HTT (0.68) | HTTTDP1PKMSMN1; SMN2LMNA | |
| Phosphoric Acid SCHEMBL27916060 | 0.79 | TDP1 (0.57) | HTTTDP1PKMKCNMA1SMN1; SMN2 | |
| SCHEMBL527567 | 0.78 | HTT (0.72) | HTTTDP1PKMSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20190330155-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392346-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10125100-B2 | Kinase inhibitors | RESPIVERT LIMITED | 2018-11-13 | — | — | US | disclosed |
| US-20180319748-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170253563-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| US-9751837-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-09-05 | — | — | US | disclosed |
| EP-3201179-A1 | DIARYL UREA DERIVATIVES AS P38 KINASE INHIBITORS | Respivert Limited (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20160102059-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016051187-A1 | DIARYL UREA DERIVATIVES AS P38 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2016-04-07 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319748-A1 | KINASE INHIBITORS | LYN, SYK, BTK | HTT 4851/4885TDP1 1294/4885PKM 2047/4885 |
| US-10125100-B2 | Kinase inhibitors | SYK, LYN, SRC | HTT 4833/4885TDP1 1981/4885PKM 1249/4885 |
| US-20190330155-A1 | KINASE INHIBITORS | SYK, LYN, BTK | HTT 4816/4885TDP1 1390/4885PKM 1515/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | HTT 4816/4885TDP1 1390/4885PKM 1515/4885 |
| US-20160102059-A1 | KINASE INHIBITORS | SYK, LYN, BTK | HTT 4791/4885TDP1 1380/4885PKM 1507/4885 |
| US-20170253563-A1 | KINASE INHIBITORS | SYK, LYN, SRC | HTT 4833/4885TDP1 1981/4885PKM 1249/4885 |
| US-10392346-B2 | Kinase inhibitors | LYN, SYK, BTK | HTT 4851/4885TDP1 1294/4885PKM 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.